Cumberland Pharmaceuticals Inc. - Common Stock (CPIX)

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to

Cumberland (CPIX) Q4 2025 Earnings Call Transcript

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

FDA approval streamlines Acetadote dosing, enhancing safety and efficiency in treating acetaminophen-related liver injury in hospitals worldwide.